Repare Therapeutics (NASDAQ:RPTX) Price Target Lowered to $4.00 at Stifel Nicolaus

Repare Therapeutics (NASDAQ:RPTX) had its target price trimmed by Stifel Nicolaus from $9.00 to $4.00 in a report issued on Friday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Separately, HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Repare Therapeutics in a report on Friday, November 8th.

Repare Therapeutics Trading Down 55.4 %

Shares of RPTX opened at $1.77 on Friday. The stock’s 50-day moving average price is $3.30 and its two-hundred day moving average price is $3.35. Repare Therapeutics has a 12 month low of $1.66 and a 12 month high of $8.49. The company has a market capitalization of $75.24 million, a PE ratio of -0.89 and a beta of 0.71.

Hedge Funds Weigh In On Repare Therapeutics

Large investors have recently added to or reduced their stakes in the business. Acadian Asset Management LLC lifted its position in shares of Repare Therapeutics by 212.1% during the 2nd quarter. Acadian Asset Management LLC now owns 417,929 shares of the company’s stock worth $1,373,000 after buying an additional 284,036 shares in the last quarter. Blue Owl Capital Holdings LP increased its position in shares of Repare Therapeutics by 8.0% during the second quarter. Blue Owl Capital Holdings LP now owns 3,372,499 shares of the company’s stock valued at $11,129,000 after acquiring an additional 250,000 shares during the last quarter. Squarepoint Ops LLC lifted its holdings in Repare Therapeutics by 428.4% during the second quarter. Squarepoint Ops LLC now owns 142,974 shares of the company’s stock worth $472,000 after acquiring an additional 115,916 shares during the period. Renaissance Technologies LLC grew its stake in Repare Therapeutics by 30.7% in the 2nd quarter. Renaissance Technologies LLC now owns 458,700 shares of the company’s stock valued at $1,514,000 after purchasing an additional 107,700 shares during the period. Finally, Marshall Wace LLP purchased a new stake in shares of Repare Therapeutics during the 2nd quarter valued at $273,000. Institutional investors own 85.09% of the company’s stock.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.